GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

Phase 1 Recruiting 186 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

An international, multicenter, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of GenSci145, as monotherapy or in combination therapy, in participants with PIK3CA-mutated, locally advanced or metastatic solid tumors.

Timeline

Start: 2026-04-01
Primary completion: 2028-11-08
Completion: 2029-02-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GenSci145	Unknown	—	—

Indications

No indication recorded.